Lecture 44Exploring intersection of GBS & chronic inflammatory demyelinating polyradiculoneuropathy, Dr YuyaoUofL Neurology · University of Louisville2:04:07
Opening Exploring intersection of GBS & chronic inflammatory demyelinating polyradiculoneuropathy, Dr Yuyao
Exploring intersection of GBS & chronic inflammatory demyelinating polyradiculoneuropathy, Dr Yuyao
Compares Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy through a case.
Read moreShow fewer
Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy present distinct diagnostic and therapeutic challenges in clinical neurology. The session examines the classic natural courses of both conditions, the four-week nadir rule for acute cases, and the eight-week progression threshold for chronic variants. It evaluates the evidence for repeating or switching intravenous immunoglobulin and plasma exchange when patients fail to improve. The discussion incorporates a challenging patient case to analyze treatment-related fluctuations, acute-onset chronic inflammatory demyelinating polyradiculoneuropathy, and autoimmune nodopathies.
Compares Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy through a case.
Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy present distinct diagnostic and therapeutic challenges in clinical neurology. The session examines the classic natural courses of both conditions, the four-week nadir rule for acute cases, and the eight-week progression threshold for chronic variants. It evaluates the evidence for repeating or switching intravenous immunoglobulin and plasma exchange when patients fail to improve. The discussion incorporates a challenging patient case to analyze treatment-related fluctuations, acute-onset chronic inflammatory demyelinating polyradiculoneuropathy, and autoimmune nodopathies.
Is it for you
Summary written with AI from the lecture and its description
What you will take away
1Guillain-Barré syndrome is a monophasic condition that typically reaches its disease nadir within four weeks of symptom onset.
2Steroid monotherapy is ineffective in Guillain-Barré syndrome but serves as both induction and maintenance therapy in chronic inflammatory demyelinating polyradiculoneuropathy.
3Clinical deterioration occurring beyond eight weeks or repeating three or more times indicates acute-onset chronic inflammatory demyelinating polyradiculoneuropathy.
4Autoimmune nodopathies are mediated by IgG4 antibodies targeting nodal structures and respond favorably to rituximab rather than intravenous immunoglobulin.
Before you start
Good fit if
Neurology residents, fellows, and practicing clinicians seeking a review of inflammatory demyelinating polyneuropathies. Several audience questions near the end are partially muffled. Explains the material in order, conversational in tone and with humour, warm toward the audience. Takes questions along the way.
Exploring intersection of GBS & chronic inflammatory demyelinating polyradiculoneuropathy, Dr Yuyao
Talk 44 of 115 of UofL Neurology Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Lehmann HC, Burke D, et al., cited for CIDP guidelines ·
Lancet Neurol. 2010 Apr;9(4):402-12
Vallat JM, Sommer C, et al., cited for CIDP disease course classification ·
J Neurol. 2020 Jul;267(7):2155-2170
Review on the misdiagnosis of CIDP ·
J Peripher Nerv Syst. 2020 Sep;25(3):209-218
Review on chronic inflammatory demyelinating polyradiculoneuropathy diagnostic pitfalls ·
J Neurol Neurosurg Psychiatry. 2017;88:346-352
Verboon C, van Doorn PA, et al., cited for treatment response rates at 4 weeks ·
Journal of Clinical Neuromuscular Disease 18(2):p 59-67, December 2016
Ottiker-Walker et al., cited for a retrospective study on plasma exchange after initial IVIG in Guillain-Barre syndrome ·
Plasma Exchange After Initial Intravenous Immunoglobulin Treatment in Guillain-Barré Syndrome: Critical Reassessment of Effectiveness and Cost-Efficiency
Ocke-Waker et al., Journal of Clinical Neuromuscular Disease, 2016 ·
Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome
Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome
Farcas et al., Lancet, 1997 ·
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial
Lancet Neurol, 2021 ·
Appropriate Number of Plasma Exchanges in Guillain-Barré Syndrome
The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome, Ann Neurol, 1997 ·
Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial
van Koningsveld et al., Lancet, 2004 ·
Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange
R. P. Kleyweg, F. G. van der Meché, 1991, case series on GBS-TRF ·
Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: A prospective study
Liselotte Ruts, Rinske van Koningsveld, Pieter A. van Doorn, 2005, retrospective/prospective studies ·
Recurrent Guillain-Barré syndrome
K. Kuijf, R. van Koningsveld, L. Ruts, B. C. Jacobs, P. A. van Doorn, 2009, study on recurrent GBS ·